The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase II trial of opaganib in patients with metastatic castration-resistant prostate cancer progressing on abiraterone or enzalutamide (NCT04207255).
 
Omer Kucuk
No Relationships to Disclose
 
Charles Smith
Employment - Apogee Biotechnology Corporation
 
Terry Plasse
Employment - RedHill Biopharma
 
Besim Ogretmen
Patents, Royalties, Other Intellectual Property - I am the Founder and CEO for a small biotech company called Lipo-Immuno Tech, LLC, which develops anti-cancer drugs.
 
Shikhar Mehrotra
No Relationships to Disclose
 
Theodore Stewart Gourdin
No Relationships to Disclose
 
Mehmet Asim Bilen
Consulting or Advisory Role - Bayer; Bristol-Myers Squibb; Eisai; EMD Serono; Exelixis; Genomic Health; Janssen; Nektar; Pfizer; Sanofi; Seagen
Research Funding - Advanced Accelerator Applications (Inst); AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Exelixis (Inst); Genentech/Roche (Inst); Incyte (Inst); Nektar (Inst); Peleton (Inst); Pfizer (Inst); Seagen (Inst); Tricon Pharmaceuticals (Inst); Xencor (Inst)
 
Bradley Curtis Carthon
Consulting or Advisory Role - Eisai
Research Funding - Alkermes (Inst); MedImmune (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb
 
Bassel Nazha
No Relationships to Disclose
 
Jamie Goldman
No Relationships to Disclose
 
Michael B. Lilly
Speakers' Bureau - Guardant Health
Research Funding - Bavarian Nordic (Inst); Bayer (Inst)